McKesson Corporation Finalizes Divestiture of Rexall and Well.ca Businesses

02 Jan, 2025

McKesson Corporation (NYSE: MCK) announced on December 30, 2024, the completion of its transaction to divest its Canada-based Rexall and Well.ca businesses. The deal, which was originally announced in September 2024, was closed with Birch Hill Equity Partners, a Canadian private equity firm. This strategic divestiture allows McKesson to focus on its core growth areas, specifically expanding its strategic oncology and biopharma platforms. By concentrating capital deployment on these key sectors, McKesson aims to accelerate its business objectives and enhance its impact on global healthcare.

The divestiture supports McKesson's broader strategy of focusing on high-priority areas within healthcare that align with its mission to deliver affordable and accessible care. McKesson remains committed to its partnerships with biopharma companies, healthcare providers, pharmacies, and other industry stakeholders to improve health outcomes worldwide.

For further information regarding the divestiture, McKesson's investor relations website offers detailed updates and insights.

McKesson Corporation is a global leader in healthcare services, dedicated to advancing health outcomes for patients. The company collaborates with a broad spectrum of organizations, including biopharma companies, manufacturers, pharmacies, care providers, and governments. Through these partnerships, McKesson delivers innovative products, services, and insights to make quality care more accessible and affordable. More about McKesson’s efforts to transform healthcare can be found on their website, McKesson.com, where they share stories of how their initiatives are making a difference.

This press release may contain forward-looking statements that involve risks and uncertainties, including the success of McKesson's strategic growth and investment plans. While the company is committed to its objectives, actual results may differ due to various factors. McKesson urges investors to review its most recent Form 10-K filed with the Securities and Exchange Commission for a comprehensive list of risk factors.

Related News

Interview